Skip to search
Skip to main content
Back to Search
Start Over
Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC -> 4x doc vs. 6x docetaxel/cyclophospham ide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer
Authors :
Harbeck, Nadia Gluz, Oleg Clemens, Michael R. Malter, Wolfram Reimer, Toralf Nuding, Benno Aktas, Bahriye Stefek, Andrea Pollmanns, Anke Lorenz-Salehi, Fatemeh Uleer, Christoph Krabisch, Petra Kummel, Sherko Liedtke, Cornelia Shak, Steven Wuerstlein, Rachel Christgen, Matthias Kates, Ronald Kreipe, Hans Heinrich Nitz, Ulrike Harbeck, Nadia Gluz, Oleg Clemens, Michael R. Malter, Wolfram Reimer, Toralf Nuding, Benno Aktas, Bahriye Stefek, Andrea Pollmanns, Anke Lorenz-Salehi, Fatemeh Uleer, Christoph Krabisch, Petra Kummel, Sherko Liedtke, Cornelia Shak, Steven Wuerstlein, Rachel Christgen, Matthias Kates, Ronald Kreipe, Hans Heinrich Nitz, Ulrike
Publication Year :
2017
Details
Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1364917642
Document Type :
Electronic Resource